logo-loader

Silence Therapeutics CEO on potential of pancreatic cancer drug

Published: 10:29 01 Jun 2015 EDT

The chief executive of Silence Therapeutics (LON:SLN), Ali Mortazavi, says there is significant commercial opportunity for the company's pancreatic cancer drug, Atu027, following encouraging treatment data.

“Currently there are only four approved drugs in pancreatic cancer,” said the CEO speaking to Proactive.  “They all have very modest improvements in overall survival so there is clear market opportunity for the company in this space.”

Mortazavi’s was speaking after biotech firm unveiled some promising early data that points to the efficacy of its treatment pancreatic cancer sufferers.
 

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

19 minutes ago